Mirai Bio and A*STAR IMCB Formed Research Partnership
The organizations have launched a collaboration to advance nucleic acid medicine delivery to lung tissues.
Updated on Sept. 22, 2026 in Life Sciences
Live Poll
Do you believe partnerships between private companies and public research institutes accelerate medical breakthroughs?
Mirai Bio and Singapore's A*STAR Institute of Molecular and Cell Biology have entered a research collaboration to improve the delivery of nucleic acid medicines. This partnership aims to address the challenge of reaching cells beyond the liver by focusing on lung epithelial and endothelial cells.
Why it matters
Delivering genetic therapies to specific tissues outside the liver is a persistent scientific obstacle due to complex biological barriers. By overcoming these hurdles, the research could unlock new therapeutic pathways for a variety of conditions affecting the lungs.
Researchers are combining a lipid nanoparticle delivery engine with specialized ligand discovery methods and endothelial biology expertise. They utilize proprietary in vivo data and machine learning algorithms to iteratively optimize nanoparticle architecture for targeted delivery.
The players
Mirai Bio
Mirai Bio is a biotechnology company based in Cambridge, Massachusetts, that specializes in lipid nanoparticle delivery systems.
A*STAR IMCB
The Institute of Molecular and Cell Biology is a Singapore-based research facility focused on advancing scientific discovery through cell and developmental biology.
The details
The collaboration leverages the combined strengths of the two institutions under the broader Flagship Pioneering and A*STAR framework. By integrating advanced machine learning with biological modeling, the team seeks to refine how nanoparticles navigate the body to reach intended lung tissues.
Timeline
September 22, 2026: Mirai Bio and A*STAR IMCB announced the research collaboration.
The Big Picture
This project operates within the Flagship Pioneering and A*STAR institutional partnership, which facilitates cross-border collaboration between international life science firms and Singaporean research institutes. This integration accelerates the translation of basic biological research into actionable medicine by bridging academic and commercial infrastructure.
The success of this delivery platform could lead to the development of new treatments for respiratory diseases that currently lack effective genetic interventions. If the technology proves viable, it may eventually shift clinical standards for how medicine is administered to lung tissue in future therapeutics.
The takeaway
This collaboration highlights the critical role of machine learning in solving complex drug delivery challenges. Future breakthroughs in nanoparticle design may eventually expand the range of diseases treatable by nucleic acid therapies beyond current liver-focused applications.
Further reading
Learn more about the latest innovations in Life Sciences.
Source note: This article includes information reported by Firstwordpharma.
Live Poll
Do you believe partnerships between private companies and public research institutes accelerate medical breakthroughs?
